Offer NuvaRing® to more of your patients, so they may join the many

Offer NuvaRing® to more of your patients,
so they may join the many satisfied women already using it1
Women who could benefit from and could
2
choose once‑monthly NuvaRing are…
• Women who would prefer a once-monthly option
• Women who are seeking a contraceptive that has demonstrated
predictable periods:1
• Low incidence of breakthrough bleeding and spotting1
• High rate of withdrawal bleeding during the ring-free week1
• Women who actively engage in the discussion about their birth
control options
2
Offer your patient once-monthly
3
easy-to-use NuvaRing
Efficacy:
• Pregnancy prevention with high rate of satisfaction1
• 99% effective, over 13 cycles
just like combined
oral contraceptives4
• Monthly dosing5
In a given 1-month period, NuvaRing must be inserted into the vagina, Plus:
removed after 3 weeks, and a new ring must be inserted 7 days later2
• Predictable periods1
• 96% of women were satisfied with NuvaRing1
2
In clinical trials, most women who used once-monthly
1
NuvaRing, experienced predictable periods
Cycle Control Results—Mean Incidence Over 13 Cycles1
Incidence of Breakthrough
Bleeding or Spotting
(Average per Cycle)
5.5%
Withdrawal
Bleeding (Mean
Incidence Over 13 Cycles)
98.5%
RING USE
RING-FREE WEEK
Day 1
Day 21
INSERT NEW RING
Day 28
Adapted from Dieben TOM et al.1
Study Design: Two open-label, noncomparative studies of NuvaRing 21/7 for 13 cycles were combined
(N=2,322). One study was performed in 52 European centres; the other in 48 centres in Canada and the US.1
2
Once-monthly NuvaRing demonstrated lower incidence
of breakthrough bleeding and spotting compared with a
6
30-µg EE COC which was significant in cycles 2 and 9
Incidence of Breakthrough Bleeding and Spotting
NuvaRing vs a 30-µg COC with LNG 6
15
Incidence of Breakthrough
Bleeding/Spotting, %
NuvaRing
COC (30-mcg EE
and 150-mcg LNG)
10
a
5
a
0
2
3
4
5
6
7
8
Treatment Cycles
9
10
11
12
13
Adapted from Oddsson K et al.6
Study Design: An open-label,
randomised, multicentre study
comparing cycle control with a
combined contraceptive vaginal ring
(N=512) and a COC (30 µg of EE and
150 µg of LNG) (N=518). The study was
designed to show if a significantly
lower incidence of breakthrough
bleeding and spotting was reported
with NuvaRing in at least one of cycles
2 to 13.
a: Difference achieved statistical
significance in cycles 2 and 9 (P<0.003).
COC=combined oral contraceptive;
EE=ethinylestradiol; LNG=levonorgestrel.
2
When you offer her once-monthly NuvaRing,
she may have questions
1. Is it as effective as the pill?
• NuvaRing was 99% effective at preventing pregnancy when used as directed
over 13 cycles, just like the pill4
2. Is it easy to insert and remove?
• Most women find NuvaRing comfortable and easy to both insert and remove3,4
• More than 96% of women rarely or never had a problem inserting or
removing NuvaRing3,4
In a given 1-month period, NuvarRing must be inserted into the vagina, removed after 3 weeks,
and a new ring must be inserted 7 days later 2
3. Will I feel it?
• Most women do not feel NuvaRing once it is in place7
4. Will my partner feel it?
• Some partners may feel NuvaRing in the vagina during intercourse,
but clinical studies found that 90% of couples did not mind3
• 84% of women said they never or rarely felt NuvaRing during intercourse3
PBS Information: NuvaRing is not listed on the PBS
References: 1. Dieben TOM et al. Obstet Gynecol 2002; 100(3): 585-593. 2. NuvaRing Approved Product Information 19 September 2011. 3. Novák A et al.
Contraception 2003; 67(3): 187-194. 4. Ahrendt H-J et al. Contraception 2006; 4(6): 451-457. 5. Timmer CJ et al. Clin Pharmacokinet 2000; 39(3): 233-242.
6. Oddsson K et al. Hum Reprod 2005; 20(2): 557-562. 7. Alexander NJ et al. Fertil Steril 2004; 82(1): 1-12.
Please review the NUVARING Product Information before prescribing. The NUVARING Product
Information is available from MSD.
Minimum PI. NuvaRing (etonogestrel/ethinylestradiol) 11.7 mg/2.7 mg. Indications: Contraception. Contraindications: Thrombotic or thromboembolic events;
cerebrovascular accident; migraine; pancreatitis with hypertriglyceridaemia; hepatic disease or tumour; diabetes mellitus; sexsteroid influenced malignancies;
pregnancy; undiagnosed vaginal bleeding; hypersensitivity to any ingredient. Precautions: Periodic checkups of blood pressure, breasts, abdomen, pelvic organs,
cervical cytology. Presence or history of thrombotic events/cerebrovascular accident; tumours; hypertriglyceridaemia; diabetes; Crohn’s disease; ulcerative colitis;
chloasma; weight changes; vaginitis; toxic shock syndrome; irregular bleeding. Discontinue if hypertension/disturbance of liver function develops; with
increased frequency/severity of migraine; recurrent jaundice; pruritus; others: see full PI. Interactions: Microsomal enzyme inducers; antibiotics;
anticoagulants; some anti-diabetics; cyclosporine; theophylline; imipramine; lamotrigine. Adverse effects: Acne; headache; migraine; depression;
emotional lability; decreased libido; abdominal pain; nausea; diarrhoea; vomiting; weight gain; breast pain; device expulsion, coital problems,
foreign body sensation; dysmenorrhoea; others: see full PI. Dosage: One ring inserted in the vagina and removed after 3 weeks on
the same day of the week as its insertion. Based on PI last amended 19 September 2011.
Copyright © 2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,
Whitehouse Station, NJ, USA. All rights reserved. Merck Sharp & Dohme(Australia)
Pty Limited. Level 4, 66 Waterloo Road, North Ryde NSW 2113. WOMN-10217060032. First issued June 2012.
NUVA 5451 BBK 05/12